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Angiogenesis has been targeted in retinopathies, psoriasis, and a variety of cancers (colon, breast, lung, and kidney). Among
these tumour types, clear cell renal cell carcinomas (RCCs) are the most vascularized tumours due to mutations of the von
Hippel Lindau gene resulting in HIF-1 alpha stabilisation and overexpression of Vascular Endothelial Growth Factor (VEGF).
Surgicalnephrectomyremainsthemosteﬃcientcurativetreatmentforpatientswithnoninvasivedisease,whileVEGFtargetinghas
resulted in varying degrees of success for treating metastatic disease. VEGF pre-mRNA undergoes alternative splicing generating
pro-angiogenic isoforms. However, the recent identiﬁcation of novel splice variants of VEGF with anti-angiogenic properties has
providedsomeinsightforthelackofcurrenttreatmenteﬃcacy.Herewediscussanexplanationfortherelapsetoanti-angiogenesis
treatment as being due to either an initial or acquired resistance to the therapy. We also discuss targeting angiogenesis via SR
(serine/arginine-rich) proteins implicated in VEGF splicing.
1.Introduction
Therapies targeting angiogenesis seek to either decrease
VEGF levels or to block its receptors resulting in the
inhibition of downstream signalling pathways such as
RAS/RAF/MEK/ERK and PI3 Kinase. Thus, molecules used
in the clinic block VEGF or inhibit the tyrosine kinase activ-
ity of the VEGF receptors. These classical strategies evidently
target endothelial cells and thus prevent angiogenesis but
may also inhibit autocrine proliferative/survival pathways
due to abnormal expression of VEGF receptors by tumour
cells of diﬀerent origins [1–9].
The main treatment commonly used is Bevacizumab
(BVZ), a humanized IgG1 monoclonal antibody against
VEGF [10]. A phase II clinical trial has shown that BVZ
can signiﬁcantly prolong the time to progression of disease
in patients with metastatic renal-cell cancer [11]. However,
only the BVZ plus interferon alpha (IFN) treatment has
obtained approval by the Food and Drugs administration
(FDA) in the United States of America and the European
Medicines Agency (EMA) in Europe following phase III
clinical assays [12, 13]. These clinical assays have demon-
strated an increase in progression-free survival associated
with the treatment combining IFN and BVZ compared to
IFN alone. Unfortunately, BVZ plus IFN did not improve
overall survival when compared to IFN monotherapy [14,
15]. Other treatments targeting the diﬀerent VEGF receptors
are Receptor Tyrosine Kinase Inhibitors (RTKI) such as
sunitinib targeting VEGFR2, PDGFR, FLT3, and c-Kit or
sorafenib targeting B-Raf, c-Raf, VEGFR2/3, PDGFR, FLT3,
and c-Kit. These compounds are used in cases of advanced
RCC with good or intermediate prognosis. Two clinical trials
showed the beneﬁt of using sunitinib for treating advanced
RCC with a greater decrease in tumour size, an increase
of progression-free survival of about nine months, and a
better quality of life [16, 17]. Another phase III clinical trial
has also demonstrated eﬃcacy of sorafenib on RCC [17].
However, as for the BVZ plus IFN combined treatment,
sunitinib or sorafenib did not increase overall survival of
RCC patients. Axitinib [18] and pazopanib [19]a r en e w
VEGFR-TKIcompoundsgeneratedforthetreatmentofRCC
but it is too early to evaluate their eﬃcacy compared to2 Journal of Nucleic Acids
sorafenib or sunitinib. The other class of compounds targets
the mTOR pathway. Patients who progressed on sorafenib or
sunitinib as well as patients who have a poor prognosis are
treated with mTOR blockers such as temsirolimus [20, 21]
or everolimus [22]. Deforolimus is also a new generation of
anti-mTOR compounds for the treatment of RCC [23].
2. Lack of Predictive Factors for the
Success/FailureofAnti-AngiogenicTherapies
One of the main problems for patients treated with anti-
angiogenic therapies is the lack of an eﬀective predictive
biomarker for their use. Many trials have tried to identify
predictive biomarkers to assist in the selection of appropriate
therapies. However, contradictory results from a number
of these studies necessitate further investigations. Indeed,
the circulating VEGF, thought to be associated with BVZ
eﬃciency, is not predictive on beneﬁt as has been shown
in a phase II trial on RCC [11, 24]. Plasma levels of VEGF
were not predictive of response to treatment by BVZ in
other cancers either [24–26]. In the same way, no correlation
had been observed with circulating endothelial cells (CECs)
or circulating endothelial progenitors (CEPs) at only early
stage, where RCC is rare to be diagnosed [27]. In summary,
identiﬁcation of predictive biomarkers for this treatment
failed even though hypertension is thought to be a good
candidate as a predictive marker of outcome with BVZ plus
INF as the ﬁrst-line treatment in advanced RCC [15, 28]a s
well as sunitinib in metastatic RCC treated patients [29].
3. DifferentBiological Effects Dependingon
Ligandsand/orReceptors Involved
VEGF binds to its receptors, which then form either
homodimers or heterodimers. Following the dimerization,
the receptors are transphosphorylated and the downstream
signalling pathways are activated. Furthermore, the kinase
domain of each type of receptor is not the same and
consequently,signallingwilldiﬀerdependingonthereceptor
involved. Thus, in the case of heterodimerization, the kinase
domain of VEGFR1 will phosphorylate diﬀerent tyrosine
sites than VEGFR2 for example [30]. The same observations
are also found with VEGFR2, and VEGFR3 [31]. Further-
more, depending on the ligand bound to the receptor, the
signalling pathway can be rather diﬀerent as has been well-
described previously by Autiero et al. [32]. The situation is
also complicated by the fact that neuropilin-1 a co-VEGFR is
overexpressed on RCC cells and induces a speciﬁc activation
of the PI3 Kinase pathway [33]. Whereas VEGFR are not
expressed on RCC cells, neuropilin overexpression mediates
potent proliferative and invasive capacities.
4. Implication of VEGFxxxbIsoforms
VEGF-A is the ﬁrst form of VEGF that was described twenty
years ago for which the codiscoverer Napoleone Ferrara was
awarded the Lasker Prize [34]. The pre-mRNA of VEGF-A
undergoes alternative splicing leading to diﬀerent isoforms
noted as VEGFxxx (xxx stands for the number of amino
acids present in proteins minus the signal peptide). The
major ones are VEGF165, VEGF189, and VEGF121. There
are also a few minor isoforms spliced from the pre-mRNA,
which are VEGF206, VEGF183, VEGF145 and VEGF148,
and VEGF111 although their functions remain less clear
(Figure 1)[ 35–40].
In 2002 Bates et al. identiﬁed a splice variant of
VEGF165, VEGF165b that is expressed in most normal
tissues and downregulated in cancers especially in RCC
[41]. Furthermore, this ﬁnding could put a full stop to
the paradox of a high level of VEGF in podocytes where
angiogenesis is not upregulated. As suggested by Bates and
Harper, the codiscoverers of VEGFxxxb, the existence of
anti-angiogenic forms of VEGF “needs reinterpretation or
at worst, require repeating the experiment with reagent that
diﬀerentiate between isoforms families” [42]. In light of
the discovery of Bates et al., these forms of VEGF may be
anti-angiogenic forms [41, 43]. After the identiﬁcation of
VEGF165b, a new sub-family of VEGFxxxb isoforms were
identiﬁed (VEGF189b, VEGF121b) (Figure 1)[ 42].
Since then, a few publications assessed the anti-
angiogenic or at least a less angiogenic outcome of VEG-
Fxxxb isoforms by, in particular, the downregulation of
VEGFR signalling pathway and a decrease of tumour growth
[44–46]. These results have been achieved in vitro on
proliferation and migration of endothelial cells along with in
vivostudies on tumour volume of RCC, prostate, melanoma,
and colorectal cancers and on experimental choroidal neo-
vascularization [44, 47–50]. Moreover, the downregulation
ofVEGF165b expressionleadstometastaticmelanomawhile
VEGF165b expression prevents metastasis of malignant
melanoma [51]. We can hypothesize that the ratio between
the pro- and the anti-angiogenic or the less angiogenic
isoforms may be crucial for the angiogenic balance. Recent
results strongly suggest that VEGFxxxb may act as an
anticancer therapy [45, 47, 48] and as an eﬃcient therapy




The identiﬁcation of VEGFxxxb isoforms has complicated
the initial notion that targeting the pro-angiogenic forms
of VEGF would be beneﬁcial for the treatment of diseases
associated with abnormal angiogenesis. Therefore, BVZ can
recognize and bind VEGFxxxb as well as VEGFxxx isoforms
since BVZ recognition motif is located in VEGFR-binding
domain of VEGF [53]. Hence, the concomitant presence
of VEGFxxx and VEGFxxxb isoforms may contribute to
the inhibition of the anti-angiogenic eﬀect of BVZ on
tumour growth [45]. This hypothesis is particularly striking
since we have detected VEGFxxx and VEGFxxxb isoforms
in 70% of the RCC we have tested (Gr´ epin, R and
Pag` es, G personal communication). Thus, BVZ can trap
the VEGFxxxb isoforms that are, by themselves, capable
of decreasing the activation of the angiogenic pathway.Journal of Nucleic Acids 3
Figure 1: Alternative splicing of VEGF-A pre-mRNA. The pre-mRNA of VEGF-A undergoes alternative splicing leading to pro-angiogenic
isoforms notated with the number of amino acids and containing as last exon, the exon 8a stemming from the Proximal Splicing Site (PSS)
located at the beginning of exon 8. The more recent subfamily of VEGF isoforms containing ﬁve members so far, are anti-angiogenic and
contain as last exon, the exon 8b resulting of the splicing at the Distal Splicing Site (DSS) located after the exon 8a.
Eﬀectively, VEGFxxxb homodimers bind to the VEGF
receptors and block the downstream signalling pathway
[44]. On the other hand, VEGFxxxb can heterodimerize
with VEGF preventing VEGF-mediated activation of VEGF
receptors [42]. Consequently, the presence of VEGFxxxb
may have a double anti-angiogenic action through (i) direct
downregulation of VEGF receptors signalling pathways and
(ii) by inhibiting VEGF activation of the pathway. This
ﬁnding could explain why patients treated with BVZ do not
have as good results as expected if VEGFxxxb isoforms are
still present.
Furthermore, treatment of breast, lung, colon, and kid-
ney cancers has combined BVZ to conventional chemother-
apies. A phase III trial of metastatic breast cancers, at
primary diagnosis treated with BVZ plus Paclitaxel, showed
a better beneﬁt on progression-free survival than Paclitaxel
alone [54]. Similarly, combination of BVZ plus Paclitaxel-
Carboplatin in a randomized study of non-small-cell lung
cancer showed a better beneﬁt than Paclitaxel-Carboplatin
alone [55]. Also, the addition of BVZ to Irinotecan, Flu-
orouracil and Leucovorin for treatment of metastatic col-
o r e c t a lc a n c e ri m p r o v e ds u r v i v a l[ 56]. Finally, a randomized
phase III trial of metastatic RCC showed the improvement
on progression-free survival of the addition of BVZ to
IFN as ﬁrst-line treatment [12]. However, the relapse to
therapy or an acquired resistance may be explained by either
the redundancy of angiogenic factors or the selection of
aggressivecells,showingthelimitofthesetreatmentsandthe
necessitytoswitchtoRTKItobypassresistancetoanti-VEGF
therapy. We can hypothesize that the chemotherapeutic
agents used in combination with BVZ may normalize the
VEGF/VEGFxxxb ratio in favour of VEGFxxxb. Hence,
targeting the “good and bad” VEGF isoforms may lead to
selection of more aggressive cells rendering the therapeutic
combination totally ineﬃcient and even deleterious. Thus,
in order to get the expected beneﬁt, two diﬀerent strategies
could be investigated: either targeting speciﬁcally the pro-
angiogenic VEGF isoform or treating patients with BVZ only
in cases where the VEGFxxxb isoforms are absent, although
it represents a third of patients as described above.
6. Regulation of VEGFSplicingLeadingto
Targeting Splicingfor Therapy
The study of VEGFxxxb isoforms regulation may be key
for targeting the angiogenic balance in cancers and other
pathologies. Most genes, like VEGF, can produce diﬀerent
transcripts, which result in the production of diﬀerent
protein isoforms. This phenomenon, known as alternative
splicing, is mainly regulated by SR proteins. One of these
proteins, ASF/SF2, has been described as a protooncogene
with it being suﬃcient to induce cell transformation [57].
These observations provide a link between angiogenesis,
cancer, and splicing. The study of VEGF splicing has
illustrated in particular the need of SR proteins such4 Journal of Nucleic Acids
Figure 2: Existing and putative therapies targeting angiogenesis in RCC. VEGFxxx forms homodimers and interacts with their receptors
inducing the activation of signalling pathways leading to increased angiogenesis. Homodimers of VEGFxxxb can bind the receptors blocking
angiogenesis.However,theexistenceandfunctionofpotentialVEGFxxx/VEGFxxxbheterodimersremainunclear.Themonoclonalantibody
Bevacizumab targets VEGFxxx blocking the VEGFR signalling pathways but also interacts with VEGFxxxb. Sorafenib and Sunitinib are
Receptor Tyrosine Kinase inhibitors that interact with the kinase domain of VEGFR and thus inactivate the downstream signalling pathways.
The VEGF gene is transcribed into a pre-mRNA that undergoes diﬀerent splicing events leading to diﬀerent isoforms. Splicing at Exon 8
will determinate the pro- or anti-angiogenic property of the produced protein. Hence, the use of the proximal splicing site (PSS) by in
particular the splicing factor ASF/SF2 leads to pro-angiogenic -VEGFxxx- forms while the use of the distal splicing site (DSS) by another
SR protein, SRp55 provides the anti-angiogenic -VEGFxxxb- forms. Combining all of this knowledge leads to propose that by acting on the
VEGFxxx/VEGFxxxb ratio through the modulation of splicing, we could modify the angiogenic potential.
as ASF/SF2 and SRp55. ASF/SF2, which is upregulated
in most tumour types [58–60], favours the production
of the pro-angiogenic isoforms, while SRp55 favours the
production of the anti-angiogenic isoforms in normal cells
[58]. Furthermore, TGFβ treatment leads to an increase in
the VEGFxxxb expression through an increase of SRp55 by
the activation of the p38MAPK pathway. In contrast, IGF-
1 stimulation leads to an increase in activated ASF/SF2 by
phosphorylation and thus an increase of VEGFxxx isoforms
[58]. All of the SR proteins are mainly regulated by SRPK
and Clk kinases. Depending on the type of SR proteins,
their phosphorylation can be mediated by speciﬁc kinases.
Thus, the IGF-1-dependent increase of VEGFxxx could be
blocked by the use of speciﬁc inhibitors of SRPK and/or
Clk kinases. Thereby, TG0003 mainly inhibits Clk kinases
and SRPIN340 inhibiting SRPK kinase, mainly involved in
ASF/SF2 activation [60]. Furthermore, chromatin structure
andassociatedmodiﬁcationsmayinﬂuencethesplicing[61].
The balance of splicing and transcription regulation depends
on several other contributing factors, such as recruitment
of RNA recognition, motif-containing proteins, or potential
associated cofactors [62]. In addition, the sequence and
the length of introns and exons play a major role for the
splicing and the following translation of the mRNA. The use
of Histone Deacetylase (HDAC) inhibitors such as sodium
butyrate has been shown to promote the production of
speciﬁc splice variants from a single pre-mRNA [63]. In
the same manner, treatment of human lung microvascular
endothelial cells (HLMECs) with sodium butyrate showed
an increase of anti-angiogenic isoforms of VEGF suggesting
that the treatment may act via a change of splicing factors
acting on the balance of pro- and anti-angiogenic isoforms
[64]. Thus, treatments already used in the clinic such as
sunitiniborsorafenibmayactthroughthesamemechanisms
leading to an increase of VEGFxxxb isoforms. Furthermore,
when expressed, VEGFxxxb may be sequestered within theJournal of Nucleic Acids 5
cytoplasm rather than secreted suggesting an intracellular
role for these isoforms [65] as was already demonstrated for
VEGF [3]. We can then predict that the combination of anti-
angiogenic therapies and targeting of SRPK activity to alter
the VEGF/VEGFxxxb balance may improve actual therapies
and be a key to increased treatment eﬃciency (Figure 2).
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